Patient case (clinical description): The patient is a 38-year-old man with cough and body ache that started 3 days ago.  He had fever and chills at the beginning and has low grade fever at the time of visit. He feels tired and sleepy. His body ache and myalgia get better after using Tylenol. The PCR test for Covid is positive. His vital signs are within normal limits with a body temperature of 37.9 C. There is no lymphadenopathy or white exudates in the pharynx.

Patient's own account: I was feeling really sick the other day, to the point that I showed up at the doctor's office. I was coughing, and my body was hurting for 3 days. I had a fever and chills and felt tired and sleepy. I got better after using Tylenol. They did a PCR Covid test on me, and it was positive! My vitals were normal, and my temperature was 37.9 C. I had no swelling around my neck or white spots on the back of my throat.

Clinical trial: (CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC

Eligibility criteria:
Inclusion Criteria:

        The study population will include individuals who tested positive for COVID-19 infection
        based on a PCR test. The study population is defined as adults ≥ 18 years of age with no
        comorbidities and absence of pre-existing conditions (see exclusion criteria below).

          -  Baseline drug screen for schedule 1 narcotics

          -  All participants are required to understand and provide informed consent before any
             assessment is performed

          -  Be willing and able to complete an online questionnaire

          -  Be able to understand and agrees to comply with planned study procedures and be
             available for all study visits

          -  Participants who have received the Pfizer or Moderna vaccine are allowed to be
             enrolled in study if they have a PCR positive test

        Exclusion Criteria:

          -  Current hospitalization

          -  Participation in any other COVID-19 trial

          -  Individuals that are taking antiviral medications

          -  Baseline lab/drug screen shows consumption of a schedule 1 narcotic

          -  Prior diagnosis of cancer and currently undergoing radiation, chemotherapy, or
             immunotherapy; excluding basal cell skin carcinoma

          -  Participants who have been diagnosed as HIV positive or taking anti-HIV therapy

          -  Female participants who are pregnant or breastfeeding, lactating, or planning a
             pregnancy during the trial.

          -  Female subjects who is/are breastfeeding or plans to breastfeed

          -  Medical disease or conditions such as high-risk comorbidities such as: diabetes,
             chronic obstructive pulmonary disease (COPD) or emphysema, history of heart attack or
             stroke, history of coronary bypass surgery or coronary angioplasty or stent, history
             of hospitalization for heart failure, etc.

          -  Demonstrated inability to comply, tell the truth (as defined by PI, study investigator
             on subjects health condition) with the study procedures

          -  History of hypersensitive or severe allergic reactions

          -  Anticipated need for immunosuppressive treatment within the next 6 months

          -  Received immunoglobulins and or any blood or blood products within the 4 months of
             being enrolled in this investigation

          -  Blood dyscrasias or significant disorder of coagulation.

          -  Severe Liver disease including chronic liver disease, fatty liver, cirrhosis or
             awaiting transplant.

          -  History of alcohol abuse or other recreational drug abuse of schedule 1 narcotics
             within 6 months of being enrolled in the study.

          -  Subjects diagnosed with:

               -  Kidney disease (CKD) | End-Stage Renal Disease (ESRD) or dialysis.

               -  A history of Calcium Oxalate kidney stones

               -  Mineral bone disorders.
No condition on gender to be admitted to the trial.
Accepts Healthy Volunteers
Subject must be at least 18 Years old.


Eligibility (NLI label): Entailment